Jan 22, 2025 · IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human therapeutics, will collaborate with Novo Nordisk …

5 days ago · Upon or before identifying a potential candidate for further development, Novo Nordisk will then take over all activities related to clinical development, regulatory submissions, …

IMMvention Therapeutix works on first-in-class Bach1 inhibitors with transformative potential as oral therapy for patients with sickle cell disease (SCD) and beyond.

Jan 23, 2025 · IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration …

Jan 22, 2025 · Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder …

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, …

IMMvention Therapeutix announced a strategic collaboration and license agreement with Novo Nordisk A/S (NVO) to co-develop oral therapies for sickle cell disease and other chronic …

IMMvention's mission is to create a globally accessible therapy, benefiting patients with limited or no access to gene therapies. Currently in preclinical stage, IMM-4800 has exceptional drug …

Jan 23, 2025 · Durham - IMMvention Therapeutix, Inc. an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic …

IMMvention Therapeutix, Inc. recently announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other …